Axsome Therapeutics Inc

Research Axsome Therapeutics Inc (AXSM) on Bullrun: market cap USD 10.57B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 10.57B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 638.50M-USD 183.17M-USD 93.89M92.6%-3.68USD 322.93MUSD 187.75MUSD 88.30M
FY2024USD 385.69M-USD 287.22M-USD 128.68M91.4%-5.99USD 315.35MUSD 180.71MUSD 57.02M
FY2023USD 270.60M-USD 239.24M-USD 145.66M90.4%-5.27USD 386.19MUSD 178.07MUSD 190.98M
FY2022USD 50.04M-USD 187.13M-USD 117.21M89.6%-4.6USD 200.84MUSD 94.26MUSD 109.56M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 10.57Bn/an/an/a
20252025-12-31USD 9.29Bn/an/an/a
20242024-12-31USD 4.12Bn/an/an/a
20232023-12-29USD 3.77Bn/an/an/a
20222022-12-30USD 3.35Bn/an/an/a
20212021-12-31USD 1.43Bn/an/an/a

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Axsome Therapeutics Inc's market cap?

Axsome Therapeutics Inc's market capitalization is USD 10.57B.

What does Axsome Therapeutics Inc do?

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.